CEO Alex Gorsky Elected Chairman of Johnson & Johnson; Bill Weldon To Step Down After 41-year Career at Johnson & Johnson

  CEO Alex Gorsky Elected Chairman of Johnson & Johnson; Bill Weldon To Step
                Down After 41-year Career at Johnson & Johnson

PR Newswire

NEW BRUNSWICK, N.J., Nov. 30, 2012

NEW BRUNSWICK, N.J., Nov. 30, 2012 /PRNewswire/ --Johnson & Johnson (NYSE:
JNJ)today announced that its Board of Directors has elected Alex Gorsky
Chairman, Board of Directors of Johnson & Johnson. Mr. Gorsky will assume the
Chairman title and additional leadership responsibilities for the global
health care company on Dec. 28, 2012; Mr. Gorsky was appointed Chief Executive
Officer of Johnson & Johnson in April 2012. Current Chairman Bill Weldon will
step down as Chairman on Dec. 28, 2012, and announced plans to retire in the
first quarter of 2013, after a brief transitional period.

"I am truly honored to succeed Bill Weldon as Chairman of Johnson & Johnson,"
said Mr. Gorsky. "Bill's leadership and contributions to Johnson & Johnson
over a 41-year career leave us well-positioned to continue addressing the
world's most prevalent diseases and unmet needs in health care. Our financial
strength, global reach, and innovations that help people live longer,
healthier lives are a proud legacy for Bill and a strong foundation for the
future of Johnson & Johnson."

"Throughout his career, leaders from the public and private sector, from
business and government, have all turned to Bill for his views on health care
and corporate matters – a tribute to his leadership of Johnson & Johnson and
his clear thinking on a broad range of complex issues and policies," said Mr.
Gorsky. "His advocacy for patients and his strong sense of corporate values
will have a lasting influence on our company and our industry."

"Serving as Chairman and CEO of Johnson & Johnson has been a privilege, and I
am confident in Alex's ability to lead the people of Johnson & Johnson to even
greater achievements," said Weldon. "I would like to thank the people of
Johnson & Johnson for all their commitment and dedication to the patients and
customers they serve. They bring to life the hope and promise of better
treatments, cures, health and well-being for those who use our products. It
has been an honor to work with them."

"The Board gave thoughtful and rigorous consideration to our governance
structure and determined that combining the chairman and CEO positions under
the strong leadership of Alex Gorsky will benefit all our stakeholders," said
Presiding Director James Cullen.

The Board also indicated that it will enhance the Board's governance structure
by expanding the duties and responsibilities of the independent Presiding
Director to include more involvement in stakeholder communications, board and
executive performance evaluations, agenda-setting and succession planning.
The duties and responsibilities of this position, which will carry the title
of Lead Director, will be discussed in detail in the Company's 2013 Proxy

About Johnson & Johnson

Caring for the world, one person at a time…inspires and unites the people of
Johnson & Johnson. We embrace research and science - bringing innovative
ideas, products and services to advance the health and well-being of people.
Our approximately 129,000 employees at more than 250 Johnson & Johnson
operating companies work with partners in health care to touch the lives of
over a billion people every day, throughout the world.

(This press release contains "forward-looking statements" as defined in the
Private Securities Litigation Reform Act of 1995. The reader is cautioned not
to rely on these forward-looking statements. These statements are based on
current expectations of future events. If underlying assumptions prove
inaccurate or unknown risks or uncertainties materialize, actual results could
vary materially from the expectations and projections of Johnson & Johnson.
Risks and uncertainties include, but are not limited to, general industry
conditions and competition; economic factors, such as interest rate and
currency exchange rate fluctuations; technological advances, new products and
patents attained by competitors; challenges inherent in new product
development, including obtaining regulatory approvals; challenges to patents;
significant adverse litigation or government action; impact of business
combinations; financial distress and bankruptcies experienced by significant
customers and suppliers; changes to governmental laws and regulations and
domestic and foreign health care reforms; trends toward health care cost
containment; increased scrutiny of the health care industry by government
agencies; changes in behavior and spending patterns of purchasers of health
care products and services; financial instability of international economies
and sovereign risk; disruptions due to natural disasters; manufacturing
difficulties or delays; and product efficacy or safety concerns resulting in
product recalls or regulatory action. A further list and description of these
risks, uncertainties and other factors can be found in Exhibit 99 of Johnson &
Johnson's Annual Report on Form 10-K for the fiscal year ended January 1,
2012. Copies of this Form 10-K, as well as subsequent filings, are available
online at, or on request from Johnson &
Johnson. Johnson & Johnson does not undertake to update any forward-looking
statements as a result of new information or future events or developments.)

SOURCE Johnson & Johnson

Contact: Press, Al Wasilewski, +1-732-524-1130, or Investors, Louise Mehrotra,
+1-732-524-6491, or Stan Panasewicz, +1-732-524-2524
Press spacebar to pause and continue. Press esc to stop.